Literature DB >> 12197929

Anemia and end-stage renal disease in the developing world.

Hédi Ben Maïz1, Ezzeddine Abderrahim, Karim Zouaghi.   

Abstract

In developing countries, multiple comorbidities such as malnutrition, parasitoses, and hemoglobinopathies contribute to the aggravation of anemia observed in patients with end-stage renal diseases. We analyze here the results of a retrospective evaluation of red-cells indices and iron parameters conducted at the end of December 2000 in 304 prevalent Tunisian patients (sex ratio, 1.05; mean age, 53.7 years) receiving chronic hemodialysis for a median duration of 49.6 months (range, 1.6 to 278). Anemia, observed in 87.8% of patients, was normochromic and normocytic in 73% of cases. Only 2% of patients had microcytic and hypochromic anemia. Iron deficiency was observed in 21.6% of anemic patients. The mean rate of hemoglobin was significantly higher in men and in patients with polycystic kidney disease as the cause of renal failure. There was a positive correlation between hemoglobin values and the quality of dialysis. Only 10.8% of patients were on recombinant human erythropoietin (rHuEPO) and 38% required regular transfusions. We conclude that anemia observed in our patients had, in most cases, the characteristics of renal anemia and could be attributed to a deficit of renal production of erythropoietin. However, for financial reasons, prescription of rHuEPO is rather restrictive and blood transfusion remains largely used. The nephrology community and dialysis providers should increase their efforts to improve the anemia care of dialyzed patients in developing countries.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197929     DOI: 10.1046/j.1525-1594.2002.07066.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  7 in total

1.  Anemia in patients on chronic hemodialysis in Cameroon: prevalence, characteristics and management in low resources setting.

Authors:  Francois Folefack Kaze; Andre-Pascal Kengne; Alex Tatang Mambap; Marie-Patrice Halle; Dora Mbanya; Gloria Ashuntantang
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

2.  Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan.

Authors:  Salah M AbuRuz; Yazan Alrashdan; Anan Jarab; Deema Jaber; Izzat A Alawwa
Journal:  Int J Clin Pharm       Date:  2013-07-25

3.  Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.

Authors:  Wanja Michael Bernhardt; Michael Sean Wiesener; Alexander Weidemann; Roland Schmitt; Wilko Weichert; Philipp Lechler; Valentina Campean; Albert Chee Meng Ong; Carsten Willam; Norbert Gretz; Kai-Uwe Eckardt
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

4.  Is soluble transferrin receptor a good marker of iron deficiency anemia in chronic kidney disease patients?

Authors:  S Gupta; B Uppal; B Pawar
Journal:  Indian J Nephrol       Date:  2009-07

Review 5.  Risk Factors for Anemia in Patients with Chronic Renal Failure: A Systematic Review and Meta-Analysis.

Authors:  Wondimeneh Shibabaw Shiferaw; Tadesse Yirga Akalu; Yared Asmare Aynalem
Journal:  Ethiop J Health Sci       Date:  2020-09

Review 6.  Chronic kidney disease in low-income to middle-income countries: the case for increased screening.

Authors:  Cindy George; Amelie Mogueo; Ikechi Okpechi; Justin B Echouffo-Tcheugui; Andre Pascal Kengne
Journal:  BMJ Glob Health       Date:  2017-05-29

7.  Meta-Analysis of Randomized Controlled Trials on Androgens versus Erythropoietin for Anaemia of Chronic Kidney Disease: Implications for Developing Countries.

Authors:  B Adamu; S M Ma'aji; P J Erwin; I M Tleyjeh
Journal:  Int J Nephrol       Date:  2012-10-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.